Series C20 March 2025

Brainomix secures £14m in Series C funding to expand medical imaging software.

The Series C round was co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund to support international expansion and clinical studies.

£14.0MSeries C

Brainomix develops artificial intelligence imaging software designed to improve clinical diagnostics for strokes and lung fibrosis. The medtech firm emerged from academic research at the University of Oxford.

Brainomix has secured £14m in Series C funding to support the expansion of its artificial intelligence imaging technology into the United States. The investment will also drive the development of its stroke and lung fibrosis diagnostic solutions.

The financing round was co-led by existing backers Parkwalk Advisors and the Boehringer Ingelheim Venture Fund. They were joined by new investor Hostplus through the IP Group Hostplus Innovation Fund, alongside participation from LifeSci Capital.

The company plans to use the capital to scale operations at its Oxford headquarters, grow its international commercial team, and fund clinical validation studies. This latest injection brings the total capital raised by the firm to £44m.

From the founder

"We would like to thank all the investors that participated, including Parkwalk and Boehringer Ingelheim Venture Fund for their continued support, and welcome Hostplus, all of whom recognise the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients. We will continue to harness our position and experience as a European market leader to achieve broad success in the US, helping improve patient care and access to life-changing therapies."

Michalis Papadakis

CEO at Brainomix

Investor perspective

"The potential for AI-powered platforms in healthcare to revolutionise diagnosis and treatment decisions is clear. Brainomix has successfully demonstrated its platform imaging software is able to deliver both significant societal impact and strong growth for investors. Parkwalk is excited to continue supporting a company that is creating comprehensive solutions to critical needs and implementing them at scale."